跳至主要内容
临床试验/NCT06465602
NCT06465602招募中2 期

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls: a Pilot Randomized Clinical Trial

University of Chile1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年5月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
Improvement in physical performance

研究概览

简要总结

Falls are unplanned events resulting in contact with a lower surface. They are common in older adults, affecting one in three individuals over 65 years old. They have serious consequences, ranging from physical injuries (fractures, traumatic brain injury) to psychological repercussions. Physical training focused on muscle strength, balance, and gait has consistently been shown to prevent falls. However, there are significant challenges in its implementation, such as the need for trained personnel and long intervention times, which are associated with high costs. Therefore, developing strategies to improve the efficiency of physical training programs in older adults is mandatory. The reduced response to physical training in older adults compared to younger individuals is a well-documented phenomenon, reflecting physiological changes associated with aging.

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for cells, mediating energy metabolism and participating in crucial processes such as DNA repair, mitochondrial function, and cell death. As we age, NAD+ levels decrease in various tissues (including the brain and muscle), contributing to the development of aging phenotypes and associated pathologies. Preclinical evidence suggests that increasing NAD+ levels reduces the appearance of aging phenotypes. During physical activity, cellular metabolic pathways that increase the demand for NAD+ to support energy production in mitochondria are activated. This increase in demand is associated with the upregulation of key enzymes involved in NAD+ degradation promoted by exercise. Considering the decrease in cellular levels of this coenzyme associated with aging, it can be hypothesized that NAD+ deficiency may play a significant role in the reduced response of older adults to training programs. Nicotinamide, a water-soluble form of vitamin B3 currently considered a nutritional supplement, is a fundamental precursor for NAD+ synthesis, capable of raising cellular levels of it. It has already been used in clinical practice in the treatment of certain endocrinological and dermatological conditions. This study aims to determine through a randomized clinical trial whether nicotinamide supplementation improves physical performance in older adults at risk of falls undergoing a physical training program.

详细描述

To test the hypothesis, a randomized pilot clinical trial will be conducted using block allocation, double-blind (patient and evaluator), designed according to the SPIRIT guidelines for drafting a trial protocol. This study involves the implementation of guided home-based physical training by a physiotherapist (2 sessions per week for 4 weeks) combined with supplementation with nicotinamide (1.5 g/day) or placebo depending on the assigned group. Improvement in physical performance will be evaluated using the Short Physical Performance Battery (SPPB), handgrip strength test, quadriceps dynamometry, posturography, and near-infrared spectroscopy (NIRS) of the quadriceps. The RedCap software will be used for randomization and data analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

盲法说明

Patients will be assigned to either Nicotinamide or placebo through block allocation. One researcher will be responsible for patient recruitment via telephone and obtaining informed consent. Another researcher will perform patient randomization and drug dispensing. Physiotherapists conducting both the initial and final physical assessments and those conducting rehabilitation sessions will be blinded to the patient's assigned group.

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 65 years or older
  • Living in the community
  • Increased risk of falls, defined as:
  • More than two falls in the last 12 months or
  • Altered balance test (unable to maintain unipedal stance > 5 seconds) or
  • SPPB score less than 10 points

排除标准

  • Known Muscle Disease (dystrophy, myopathy, or similar)
  • Motor sequelae of stroke
  • Joint pathology with severe pain preventing strength exercises
  • Cognitive impairment that renders the informed consent process impossible.

研究组 & 干预措施

Nicotinamide supplementation group

Experimental

At the beginning and end of the study, blood samples will be taken for the measurement of IL-6, CCL2, TNF-alpha, and NFL, and participants will be assessed using the Short Physical Performance Battery (SPPB), quadriceps dynamometry (LY-D Lynx Dynamo), quadriceps oxygen saturation (with NIRS), and posturography to determine the center of pressure (COP) area with the HUR BTG4 posturography system, and SmartBalance® software. Subjects will receive 1.5 grams per day of nicotinamide, orally, for 30 days. During this period, they will undergo a home-based physical training program guided by a physiotherapist. The sessions will be 50 minutes long (10 minutes warm-up, 30 minutes strength and balance training, and 10 minutes flexibility), twice a week.

干预措施: Nicotinamide (Drug)

Placebo group

Placebo Comparator

Same physical evaluation and blood sampling as the experimental group. The subjects will receive 1.5 grams per day of placebo (talc, the medium in which nicotinamide is prepared), orally, for 30 days. The bottle and the capsules will be of the same physical characteristics (shape, color, and flavor) in both groups. During that period, patients will assess patient adherence and possible adverse effects.

干预措施: Placebo (Drug)

结局指标

主要结局

Improvement in physical performance

时间窗: Four weeks

Assess the change in total Short Physical Performance Battery (SPPB) performance from baseline to post-4 weeks

次要结局

  • Posturography(Four weeks)
  • Dynamometry(Four weeks)
  • Quadriceps saturation(Four weeks)
  • Plasma sample analysis(Four weeks)
  • Adherence to medication(Four weeks)
  • Adverse effects(Four weeks)

研究者

发起方
University of Chile
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验